日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

New vaccine protects the previously infected

By WANG XIAOYU | China Daily | Updated: 2021-09-24 09:59
Share
Share - WeChat
Taxi driver Zheng Ruiwen (front) puts on a protective gown before setting off to transport COVID-19 nucleic acid samples in Putian, Fujian province, on Sept 23, 2021. [Photo by ZHANG BIN/CHINA NEWS SERVICE]

Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.

The vaccine candidate is 92 percent effective against the Gamma variant first identified in Brazil, and 59 percent against the Mu variant first detected in Colombia, according to joint statement issued by the company and the Coalition for Epidemic Preparedness Innovations, a nonprofit organization that funded the clinical trial.

The vaccine's overall efficacy rate against all strains in the study was 67 percent. It was also 100 percent effective in preventing severe cases and hospitalizations, and nearly 84 percent effective in preventing moderate to severe cases, the statement said.

The vaccine is the "first COVID-19 vaccine to demonstrate significantly reduced risk of COVID-19 disease in previously infected individuals, a growing and increasingly important population as SARS-CoV-2(the novel coronavirus that causes the disease) continues to spread globally", it said.

The protein-based vaccine uses protein fragments of the virus to trigger immune responses, and requires the use of an adjuvant to achieve desired protection.

Clover Biopharmaceuticals, which is based in Chengdu, Sichuan province, said its adjuvant is supplied by the US company Dynavax.

More than 30,000 adults-some of them elderly-in the Philippines, Brazil, Colombia, South Africa and Belgium were enrolled in mid- and late-stage clinical trials. They were either given two doses administered 21 days apart or a placebo.

Like the inactivated vaccines widely deployed in China, the experimental vaccine can be stored at regular refrigerated temperatures of 2 to 8 C, making its transportation and distribution easier.

The company said it plans to submit applications for conditional market approval to global regulatory authorities in the fourth quarter of the year and is aiming for a potential market launch by the end of the year.

Clover Biopharmaceuticals is also a supplier to COVAX, an international initiative that distributes vaccines to low- and middle-income countries.

The company signed an advance purchase agreement with Gavi, one of the co-leaders of COVAX, in late June to provide 414 million doses of its vaccine to the initiative by next year.

However, the product has to first gain emergency use authorization from the World Health Organization, which is anticipated in the fourth quarter of this year, according to Gavi.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 亚洲国产一区视频 | 欧美两性网 | 免费精品一区二区三区在线观看 | 精品欧美一区二区三区久久久 | 精品欧美乱码久久久久久1区2区 | 三极片在线观看 | 亚洲成av人片在线观看 | 青青久久 | 欧美在线一区二区三区 | 天天噜夜夜操 | 二区三区视频 | 亚洲成人中文字幕 | 欧美日韩国产在线人成dvd | 女人叉开腿让男人桶 | 日韩欧美一区二区三区在线视频 | 亚洲高清国产品国语在线观看 | 乱码中文字幕人成在线 | 欧美影院 | 欧美一区二区三区在线观看视频 | 亚洲一区二区三区在线 | 99精彩视频 | 一级一级毛片免费看 | 九九热视频在线观看 | 在线播放一区二区三区 | 国产男女交性视频播放 | 九色九色久综色鬼在线 | 日韩精品影视 | 亚洲情a成黄在线观看动 | 日本精品久久久久久久久免费 | 天天躁日日躁狠狠很躁 | 欧美一级特黄毛片免费 | 欧美精品成人a多人在线观看 | 日本午夜精品一区二区三区电影 | 青草青草久热精品视频在线网站 | 亚洲色图150p | 亚洲精品日本高清中文字幕 | 欧美精品免费线视频观看视频 | 欧美久久久久久久一区二区三区 | 亚洲精品久久久蜜桃 | 毛片大全免费看 | 亚洲综合色站 |